TBE
MCID: TCK001
MIFTS: 58

Tick-Borne Encephalitis (TBE)

Categories: Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Tick-Borne Encephalitis

MalaCards integrated aliases for Tick-Borne Encephalitis:

Name: Tick-Borne Encephalitis 12 73 20 58 15 70
Siberian Tick-Borne Encephalitis 12 70
Encephalitis, Tick-Borne 44 17
Western European Tick-Borne Encephalitis 12
Russian Spring-Summer Encephalitis 12
Encephalitis, Far Eastern Russian 70
Encephalitis, Central European 70
Central European Encephalitis 12
West-Siberian Encephalitis 12
Encephalitis Tick-Borne 54
Taiga Encephalitis 12
Far Eastern Tbe 12
Tbe 58

Characteristics:

Orphanet epidemiological data:

58
tick-borne encephalitis
Inheritance: Not applicable; Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare infectious diseases


Summaries for Tick-Borne Encephalitis

Disease Ontology : 12 A viral infectious disease that results in inflammation located in brain, has material basis in Tick-borne encephalitis virus, which is transmitted by Ixodes ticks. The infection has symptom drowsiness, has symptom confusion, has symptom sensory disturbances, and has symptom paralysis.

MalaCards based summary : Tick-Borne Encephalitis, also known as siberian tick-borne encephalitis, is related to meningoencephalitis and encephalitis, and has symptoms including confusion, drowsiness and paralysis. An important gene associated with Tick-Borne Encephalitis is SCRIB (Scribble Planar Cell Polarity Protein), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Formaldehyde and Dimenhydrinate have been mentioned in the context of this disorder. Affiliated tissues include brain, kidney and skeletal muscle, and related phenotypes are csf pleocytosis and fatigue

Wikipedia : 73 Tick-borne encephalitis (TBE) is a viral infectious disease involving the central nervous system. The... more...

Related Diseases for Tick-Borne Encephalitis

Diseases related to Tick-Borne Encephalitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 327)
# Related Disease Score Top Affiliating Genes
1 meningoencephalitis 31.7 IL10 CXCL10 ALB
2 encephalitis 31.6 TLR3 RSAD2 IL10 IFNB1 DDX58 CXCL10
3 aseptic meningitis 31.1 IL10 CXCL13 CCL3
4 west nile virus infection 31.0 OAS1 CCR5
5 poliomyelitis 30.9 TLR3 IL10 IFNA1 DDX58
6 dengue virus 30.8 RSAD2 OAS3 IVNS1ABP DDX58 CD209
7 west nile encephalitis 30.8 OAS3 OAS1 CCR5
8 west nile virus 30.7 RSAD2 OAS1 IFNA1 DDX58 CD209 CCR5
9 bacterial infectious disease 30.7 TLR3 IL10 IFNB1 CCL3
10 viral encephalitis 30.6 TLR3 IL10 IFNB1 IFNA1 CXCL10
11 yellow fever 30.6 RSAD2 OAS1 IFNB1 DDX58 CXCL10 CCR5
12 exanthem 30.5 IL10 IFNA1 ALB
13 venezuelan equine encephalitis 30.4 IFNB1 IFNA1 CXCL10
14 herpes zoster 30.4 TLR3 IL10 IFNA1 CCR5
15 asymptomatic neurosyphilis 30.4 CXCL13 CXCL10
16 syphilis 30.4 CD209 CCR5 ALB
17 disease by infectious agent 30.4 IL10 IFNB1 IFNA1 CD209 CCR5 CCL3
18 neurosyphilis 30.4 IL10 CXCL13 CXCL10
19 toxoplasmosis 30.4 IL10 CCR5 CCL3
20 dengue disease 30.3 IVNS1ABP IL10 IFNB1 IFNA1 CD209 CCL3
21 optic neuritis 30.3 IL10 CXCL10 CCR5
22 zika fever 30.3 TLR3 DDX58 CD209
23 radiculopathy 30.3 IL10 IFNA1 CCL3
24 plague 30.2 IL10 DDX58 CCR5 ALB
25 neuritis 30.1 IL10 CXCL11 CXCL10 CCR5 CCL3
26 thrombocytopenia 30.1 IL10 IFNB1 IFNA1 CXCL10 CD209 ALB
27 herpes simplex 30.1 TLR3 OAS1 IFNB1 IFNA1 DDX58 CD209
28 japanese encephalitis 30.1 TLR3 RSAD2 IVNS1ABP IFNB1 IFNA1 DDX58
29 crimean-congo hemorrhagic fever 30.1 IFNB1 IFNA1 DDX58 CXCL10
30 rubella 30.1 TLR3 IL10 IFNB1 DDX58
31 rabies 30.0 TLR3 IFNA1 DDX58 CXCL10 ALB
32 chickenpox 30.0 IL10 IFNB1 IFNA1 ALB
33 measles 30.0 TLR3 OAS1 IFNB1 IFNA1 DDX58 CD209
34 west nile fever 29.9 OAS3 OAS1 IFNA1 CXCL10 CD209 CCR5
35 pneumonia 29.9 TLR3 IL10 CXCL10 CCL3 ALB
36 covid-19 29.9 IFNB1 IFNA1 CXCL10
37 hepatitis b 29.9 TLR3 IFNB1 IFNA1 ALB
38 mouth disease 29.8 TLR3 OAS1 IL10 IFNA1 DDX58 CD209
39 mumps 29.8 TLR3 IL10 IFNB1 IFNA1 CXCL10
40 autoimmune disease 29.8 IL10 IFNB1 IFNA1 CXCL10 CCR5
41 hantavirus hemorrhagic fever with renal syndrome 29.8 IFNB1 DDX58 CXCL10 ALB
42 hepatitis e 29.7 TLR3 IFNL3 IFNB1 DDX58 ALB
43 hepatitis 29.7 RSAD2 IFNA1 DDX58 CXCL10
44 proteasome-associated autoinflammatory syndrome 1 29.7 IL10 IFNA1 CXCL10 CCL3 ALB
45 stomatitis 29.6 RSAD2 IL10 IFNB1 IFNA1 DDX58
46 influenza 29.4 TLR3 RSAD2 IVNS1ABP IFNB1 IFNA1 DDX58
47 viral infectious disease 29.1 TLR3 OAS1 IVNS1ABP IL10 IFNB1 IFNA1
48 skin disease 28.9 IL10 IFNA1 DDX58 CXCL11 CXCL10 ALB
49 multiple sclerosis 28.4 TLR3 IL10 IFNB1 IFNA1 CXCL13 CXCL11
50 powassan encephalitis 11.3

Graphical network of the top 20 diseases related to Tick-Borne Encephalitis:



Diseases related to Tick-Borne Encephalitis

Symptoms & Phenotypes for Tick-Borne Encephalitis

Human phenotypes related to Tick-Borne Encephalitis:

58 31 (show top 50) (show all 63)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 csf pleocytosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0012229
2 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
3 anorexia 58 31 frequent (33%) Frequent (79-30%) HP:0002039
4 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
5 myalgia 58 31 frequent (33%) Frequent (79-30%) HP:0003326
6 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
7 leukopenia 58 31 frequent (33%) Frequent (79-30%) HP:0001882
8 nausea 58 31 frequent (33%) Frequent (79-30%) HP:0002018
9 abnormality of serum cytokine level 58 31 frequent (33%) Frequent (79-30%) HP:0011112
10 viremia 58 31 frequent (33%) Frequent (79-30%) HP:0020071
11 depressivity 58 31 occasional (7.5%) Occasional (29-5%) HP:0000716
12 tremor 58 31 occasional (7.5%) Occasional (29-5%) HP:0001337
13 dysphagia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002015
14 hearing impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0000365
15 visual impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0000505
16 cognitive impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0100543
17 photophobia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000613
18 vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002013
19 skeletal muscle atrophy 58 31 occasional (7.5%) Occasional (29-5%) HP:0003202
20 thrombocytopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001873
21 back pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0003418
22 ophthalmoplegia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000602
23 vertigo 58 31 occasional (7.5%) Occasional (29-5%) HP:0002321
24 meningitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001287
25 sensory impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0003474
26 elevated c-reactive protein level 58 31 occasional (7.5%) Occasional (29-5%) HP:0011227
27 tinnitus 58 31 occasional (7.5%) Occasional (29-5%) HP:0000360
28 elevated erythrocyte sedimentation rate 58 31 occasional (7.5%) Occasional (29-5%) HP:0003565
29 leukocytosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001974
30 speech apraxia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011098
31 excessive daytime somnolence 58 31 occasional (7.5%) Occasional (29-5%) HP:0001262
32 personality changes 58 31 occasional (7.5%) Occasional (29-5%) HP:0000751
33 increased circulating igm level 58 31 occasional (7.5%) Occasional (29-5%) HP:0003496
34 limb pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0009763
35 incoordination 58 31 occasional (7.5%) Occasional (29-5%) HP:0002311
36 paralysis 58 31 occasional (7.5%) Occasional (29-5%) HP:0003470
37 hyperkinetic movements 58 31 occasional (7.5%) Occasional (29-5%) HP:0002487
38 increased circulating igg level 58 31 occasional (7.5%) Occasional (29-5%) HP:0003237
39 abnormal autonomic nervous system physiology 58 31 occasional (7.5%) Occasional (29-5%) HP:0012332
40 tongue fasciculations 58 31 occasional (7.5%) Occasional (29-5%) HP:0001308
41 stiff neck 58 31 occasional (7.5%) Occasional (29-5%) HP:0025258
42 abnormal glossopharyngeal nerve morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:3000047
43 decreased vigilance 58 31 occasional (7.5%) Occasional (29-5%) HP:0032044
44 abnormality of the vestibular nerve 58 31 occasional (7.5%) Occasional (29-5%) HP:0011392
45 diminished ability to concentrate 58 31 occasional (7.5%) Occasional (29-5%) HP:0031987
46 facial palsy 58 31 very rare (1%) Very rare (<4-1%) HP:0010628
47 elevated hepatic transaminase 58 31 very rare (1%) Very rare (<4-1%) HP:0002910
48 abnormal myocardium morphology 58 31 very rare (1%) Very rare (<4-1%) HP:0001637
49 psychosis 58 31 very rare (1%) Very rare (<4-1%) HP:0000709
50 coma 58 31 very rare (1%) Very rare (<4-1%) HP:0001259

Symptoms:

12
  • confusion
  • drowsiness
  • paralysis
  • sensory disturbances

GenomeRNAi Phenotypes related to Tick-Borne Encephalitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.83 GSN
2 Decreased viability GR00055-A-2 9.83 GSN
3 Decreased viability GR00055-A-3 9.83 GSN
4 Decreased viability GR00249-S 9.83 ALB TLR3
5 Decreased viability GR00342-S-1 9.83 TLR3
6 Decreased viability GR00342-S-2 9.83 TLR3
7 Decreased viability GR00386-A-1 9.83 ALB CCL3 IFNB1 IVNS1ABP SCRIB
8 Decreased viability GR00402-S-2 9.83 OAS1 OAS2 TLR3
9 Increased the percentage of infected cells GR00402-S-1 8.62 IL10 TLR3

MGI Mouse Phenotypes related to Tick-Borne Encephalitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 ALB CCR5 DDX58 IFNB1 IL10 SCRIB

Drugs & Therapeutics for Tick-Borne Encephalitis

Drugs for Tick-Borne Encephalitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 26)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
2
Dimenhydrinate Approved Phase 4 523-87-5 441281
3
Lactitol Approved, Investigational Phase 4 585-86-4 157355
4
Polygeline Experimental Phase 4 66455-30-9
5 Immunologic Factors Phase 4
6 Disinfectants Phase 4
7 Pharmaceutical Solutions Phase 4
8 Immunoglobulins Phase 4
9 Antibodies Phase 4
10 Vaccines Phase 4
11 Anti-Infective Agents Phase 3
12
Acyclovir Approved 59277-89-3 2022
13
Ceftriaxone Approved 73384-59-5 5479530 5361919
14
Doxycycline Approved, Investigational, Vet_approved 564-25-0 54671203
15
Thiethylperazine Approved, Withdrawn 1420-55-9 5440
16
Granisetron Approved, Investigational 109889-09-0 3510
17 Antiviral Agents
18 Antitubercular Agents
19 Antiemetics
20 Antibiotics, Antitubercular
21 Antiparasitic Agents
22 Anti-Bacterial Agents
23
dipyrone 522325
24 Antimalarials
25 Antiprotozoal Agents
26 Antipyretics

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 Open-Label, Follow-up, Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated Using a Rapid Immunization Schedule (Follow-up to Study 225) Completed NCT00163540 Phase 4
2 Open-label Follow-up Study to Investigate the Seropersistence of TBE Antibodies and the Booster Response to a Tick-borne Encephalitis Vaccine in Children and Adolescents Aged 3 - 18 Years Completed NCT00161967 Phase 4
3 Open-label Phase IV Study to Investigate the Seropersistence of Tick Borne Encephalitis (TBE) Virus Antibodies After the First Booster and the Response to a Second Booster Vaccination With FSME-IMMUN 0.5ml in Adults (Follow Up to Study 223) Completed NCT00503529 Phase 4
4 Open-label Phase Iv Study To Investigate The Seropersistence Of Tick-borne Encephalitis (Tbe) Virus Antibodies After The First Booster And The Response To A Second Booster Vaccination With Fsme-immun In Children, Adolescents And Young Adults (Follow-up To Study 700401) Completed NCT00894686 Phase 4
5 Open-label Phase 4 Study to Investigate the Seropersistence of Tick-borne Encephalitis (TBE) Virus Antibodies From 7 to 10 Years After the First Booster and the Response to a Second Booster Vaccination With FSME-IMMUN 0.5ml in Adults Completed NCT01582698 Phase 4
6 A Phase IV, Open-label, Multi-center Follow-up Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE Completed NCT01106482 Phase 4
7 Phase 4 Clinical Trial of Cervico-vaginal Immune Responses Following Three Right Deltoid or Right Thigh Intramuscular Immunisations With TicoVac (Tick Borne Encephalitis Virus [TBEV]) Vaccine in Adult Female Participants Completed NCT01710189 Phase 4 TicoVac
8 TBE (Tick-borne Encephalitis ) Vaccination in Allergic Patients Completed NCT02511535 Phase 4
9 A Phase IV, Open-label, Single-center Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules Completed NCT01562444 Phase 4
10 Characterization of Humoral and Cellular Immunity of Low and High-responders After TBE Vaccination Completed NCT00804219 Phase 4
11 Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years Completed NCT00161785 Phase 4
12 A Phase IV, Uncontrolled, Open-Label, Multi-Center Study in Children and Adolescents: Evaluation of Long-Term Immunogenicity in Subjects Boosted With a New Pediatric TBE Vaccine (Free of Protein-Derived Stabilizer) in Study V48P4E1, Five Years After First Booster Immunization Completed NCT00452621 Phase 4
13 A Phase IV, Randomized, Open-Label, Multi-Center Study in Adults: Evaluation of Long-Term Immunogenicity in Subjects Boosted With a New TBE Vaccine for Adults (Free of Protein-Derived Stabilizer) in Study V48P2E1, 5 Years After First Booster Immunization and Evaluation of Booster Kinetics in Subjects Boosted With a New TBE Vaccine for Adults (Free of Protein-Derived Stabilizer), 5 Years After First Booster Immunization Completed NCT00311493 Phase 4
14 A Phase IV, Randomized, Controlled, Single-Blind, Multi-Center Study in Children to Evaluate the Safety, Tolerability and Immunogenicity of Two TBE Vaccines Administered According to Two Different Schedules. Completed NCT00311441 Phase 4
15 Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years Completed NCT00161954 Phase 4
16 Influence of Persistent CMV-infection on Immune Senescence Evaluated With a Prospective Vaccination Trial Against Tick-borne Encephalitis Virus in Healthy Elderly Individuals (CYTEL-Study) Completed NCT00461695 Phase 4
17 A Phase IV, Uncontrolled, Open-label, Single-center Study in Adolescents and Adults: Evaluation of Immunogenicity and Safety of the First Booster Immunization With Novartis' TBE Vaccine for Adults in Participants of Study V48P7 and Long-term Evaluation of Immunogenicity up to 5 Years After First Booster Immunization Completed NCT00387634 Phase 4
18 Application of a TBE-Vaccine in Obese Persons Active, not recruiting NCT04017052 Phase 4 FSME-IMMUN Vaccine
19 Long Term Immunogenicity up to 15 Years After the First Booster Immunization With GSK Biologicals' Encepur Adults (Polygeline-free Tick-Borne Encephalitis Vaccine for Adults) in Adults Who Received 1 of 3 Different Primary Vaccination Schedules Active, not recruiting NCT03294135 Phase 4
20 Primary TBE Vaccination for the Elderly Not yet recruiting NCT04573205 Phase 4 FSME-IMMUN Vaccine
21 Open-label, Multicenter, Follow-up Phase III Study to Investigate the Safety of the Third Vaccination of FSME-IMMUN NEW in Volunteers Aged 16 to 66 Years Completed NCT00161876 Phase 3
22 Single-blind, Randomized, Phase 3B Study in Children Aged 1 - 11 Years to Investigate the Immunogenicity, Safety and Interchangeability of Two Tick-borne Encephalitis (Tbe) Vaccines Administered According to a Conventional Schedule Completed NCT00840801 Phase 3
23 Humoral Response to TBE Vaccine in Elderly (50+ Year Olds) After Changed Dosage Intervals/Number of Doses? Completed NCT01361776 Phase 2, Phase 3
24 Humoral Response to TBE Vaccine in Elderly (50+ Year Olds) After Changed Dosage Intervals/Number of Doses? Completed NCT02318069 Phase 2, Phase 3
25 Open-label Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years Completed NCT00161863 Phase 3
26 Open-Label Phase 3b Clinical Study to Evaluate the Immunogenicity and Safety of FSME-IMMUN 0.5 ml With the First and Second Vaccination Being Administered According to a Rapid Immunization Schedule in Healthy Adults Aged 16 Years or Older Completed NCT00460486 Phase 3
27 Multicentre Randomized Double-Blind Phase II/III Study on the Safety and Immunogenicity of Three Vaccinations With TICOVAC in Two Dosages in Healthy Children Aged Between Six Months and Three Years Completed NCT00161746 Phase 2, Phase 3
28 Single-blind, Randomized, Multicenter Comparison of FSME IMMUN NEW and ENCEPUR: Safety and Tolerability of Two Vaccinations in Healthy Volunteers Aged 16 to 65 Years. Completed NCT00161824 Phase 3
29 A Phase III, Randomized, Observer-blind, Controlled, Multi-center Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of One and Two Intramuscular Doses of Influenza Vaccine Versus Control Vaccines in Healthy Subject Aged 6 to <72 Months Completed NCT00644059 Phase 3
30 A PHASE 3, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF A TICK-BORNE ENCEPHALITIS VACCINE IN HEALTHY JAPANESE PARTICIPANTS 1 YEAR OF AGE AND OLDER Recruiting NCT04648241 Phase 3
31 Clinical Study to Test the Immunogenicity of Variant Schedules for TBE Rapid Immunisation Using Inactivated TBE (FSME) Vaccine Unknown status NCT00890422 Phase 2
32 Characterization of Humoral and Cellular Immunity for Tick-borne Encephalitis (TBE) Vaccination in Allogeneic Blood and Marrow Graft Recipients: a Pilot Study Completed NCT01991067 Phase 2
33 Double-blind, Randomized, Multicenter Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years. Completed NCT00161798 Phase 2
34 Double-blind, Randomized, Multicenter Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years. Completed NCT00161772 Phase 2
35 Follow-up Study to Investigate the Safety and Immunogenicity of a Third Vaccination With Three Different Antigen Concentrations of FSME IMMUN NEW in Children Aged 1 to 6 Years Completed NCT00161850 Phase 2
36 Follow-up Study to Investigate the Safety and Immunogenicity of a Third Vaccination With Three Different Antigen Concentrations of FSME IMMUN NEW in Children Aged 6 to 16 Years Completed NCT00161889 Phase 2
37 A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL) Against Tick-Borne Encephalitis (TBE) for NIAID Workers Manipulating Tick-Borne Encephalitis Virus (TBEV) in the Laboratory Terminated NCT01031537 Phase 2
38 Phase 1 Study of the Safety and Immunogenicity of Tick-Borne Langat/Dengue 4 Chimera (LGT(TP21)/DEN4), a Live Attenuated Vaccine for Tick-Borne Encephalitis Completed NCT00118924 Phase 1
39 Prospective Study of the Etiology, Pathogenesis, Clinical Picture and Outcome of Aseptic Meningitis in Slovenia Unknown status NCT02328469 symptomatic therapy;Ceftriaxone or Doxycycline;Acyclovir
40 Postencephalitic Symptoms After Tick Borne Encephalitis Unknown status NCT00941590
41 Management of Patients With Tick-borne Encephalitis and Positive Anti-Lyme Borreliae Antibody Results Unknown status NCT02463942 Doxycycline;Symptomatic therapy
42 Multicenter Phase IV Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children Completed NCT00163618
43 Tick-Borne Encephalitis Virus and Lyme Borreliae Causing Coillness, Coinfection, or Just Coincidence. A Prospective Observational Study Completed NCT03958058 Anti-borrelial antibiotic therapy
44 Antibiotic Therapy for Patients With Tick-borne Encephalitis and Borrelial Antibodies in Serum Recruiting NCT03956446 Doxycycline;Symptomatic therapy
45 Fever After Tick Bite (FATB) Study; Determining the Etiology of Tick-Borne Human Infections in Northern Europe Recruiting NCT03932448

Search NIH Clinical Center for Tick-Borne Encephalitis

Cochrane evidence based reviews: encephalitis, tick-borne

Genetic Tests for Tick-Borne Encephalitis

Anatomical Context for Tick-Borne Encephalitis

The Foundational Model of Anatomy Ontology organs/tissues related to Tick-Borne Encephalitis:

19
Brain

MalaCards organs/tissues related to Tick-Borne Encephalitis:

40
Brain, Kidney, Skeletal Muscle, Medulla Oblongata, Tongue, Lung, T Cells

Publications for Tick-Borne Encephalitis

Articles related to Tick-Borne Encephalitis:

(show top 50) (show all 4334)
# Title Authors PMID Year
1
C-terminal fragment of human laminin-binding protein contains a receptor domain for venezuelan equine encephalitis and tick-borne encephalitis viruses. 61 54
19961413 2009
2
[Humoral immune response to structural and nonstructural proteins of tick-borne encephalitis virus in the natural history of the disease]. 54 61
18756813 2008
3
[Secretion of tick-borne encephalitis virus glycoproteins E and NS1 heterocomplex in the late stage of infection]. 54 61
9304300 1997
4
Increasing awareness for tick-borne encephalitis virus using small ruminants as suitable sentinels: Preliminary observations. 61
33732862 2021
5
Phylogenetic analysis of tick-borne encephalitis virus strains found in an engorged tick and traveler returning from Russia. 61
33571754 2021
6
Three Babesia species in Ixodes ricinus ticks from migratory birds in Sweden. 61
33794970 2021
7
New Approaches to the Prevention and Treatment of Viral Diseases. 61
33811524 2021
8
Reply to Schmitt HJ et al.: 'Response to: "Patients with breakthrough tick-borne encephalitis suffer a more severe clinical course and display extensive magnetic resonance imaging changes"'. 61
33501726 2021
9
Comparison of whole genomes of tick-borne encephalitis virus from mountainous alpine regions and regions with a lower altitude. 61
33486691 2021
10
[Expert consensus on informed consent for vaccination (part two)]. 61
33706469 2021
11
The Impact of Tick-Borne Diseases on the Bone. 61
33806785 2021
12
Projecting the potential distribution of ticks in China under climate and land use change. 61
33798559 2021
13
[Expert consensus on informed consent for vaccination (part two)]. 61
33706426 2021
14
Molecular detection and phylogenetic analysis of Borrelia miyamotoi strains from ticks collected in the capital region of Finland. 61
33249364 2021
15
Exploration of binary protein-protein interactions between tick-borne flaviviruses and Ixodes ricinus. 61
33676573 2021
16
Insights into the molecular basis of tick-borne encephalitis from multiplatform metabolomics. 61
33690602 2021
17
Tick-Borne Encephalitis Virus Seropositivity among Tick Infested Individuals in Serbia. 61
33807559 2021
18
Survey to detect tick-borne encephalitis virus from human-feeding ticks in Hokkaido, Japan. 61
33755237 2021
19
Emerging infectious encephalitides. 61
33767094 2021
20
Detection of Tick-Borne Pathogens in Ticks from Dogs and Cats in the Yamagata Prefecture of Japan in 2018. 61
32863354 2021
21
Different Cross-Reactivities of IgM Responses in Dengue, Zika and Tick-Borne Encephalitis Virus Infections. 61
33807442 2021
22
Comparison of Three Serological Methods for the Epidemiological Investigation of TBE in Dogs. 61
33671962 2021
23
Microbiological Outcomes Associated With Low Leukocyte Counts in Cerebrospinal Fluid. 61
33575417 2021
24
Geographic distribution and modeling of ticks in the Republic of Korea and the application of tick models towards understanding the distribution of associated pathogenic agents. 61
33667830 2021
25
Antiviral Activity of 7-Substituted 7-Deazapurine Ribonucleosides, Monophosphate Prodrugs, and Triphoshates against Emerging RNA Viruses. 61
33395259 2021
26
Changing the Recipe: Pathogen Directed Changes in Tick Saliva Components. 61
33673273 2021
27
Crystal structure of a tick-borne flavivirus RNA-dependent RNA polymerase suggests a host adaptation hotspot in RNA viruses. 61
33406260 2021
28
Immunity to TBEV Related Flaviviruses with Reduced Pathogenicity Protects Mice from Disease but Not from TBEV Entry into the CNS. 61
33652698 2021
29
No evidence for African swine fever virus DNA in haematophagous arthropods collected at wild boar baiting sites in Estonia. 61
33527715 2021
30
[Epidemiology, diagnosis, and prevention of tick-borne encephalitis in Poland and selected european countries - a position statement of the polish group of experts]. 61
33734218 2021
31
Low Virus-Specific IgG Antibodies in Adverse Clinical Course and Outcome of Tick-Borne Encephalitis. 61
33562267 2021
32
The Kynurenine Pathway is Differentially Activated in Children with Lyme Disease and Tick-Borne Encephalitis. 61
33557172 2021
33
Long-term presence of tick-borne encephalitis virus in experimentally infected bank voles (Myodes glareolus). 61
33690089 2021
34
Susceptibility of Tick-Borne Encephalitis Virus to Inactivation by Heat, Acidic pH, Chemical, or UV Treatment. 61
32623454 2021
35
Vaccination against tick-borne encephalitis (TBE) after autologous and allogeneic stem cell transplantation. 61
33483213 2021
36
Corrigendum to "Crystal structure of the NS3 helicase of tick-borne encephalitis virus" [Biochem. Biophys. Res. Commun. 528(3) (2020) 601-606]. 61
33468308 2021
37
[First Danish case of tick-borne encephalitis virus vaccine failure]. 61
33660602 2021
38
The Stable Matching Problem in TBEV Enzootic Circulation: How Important Is the Perfect Tick-Virus Match? 61
33477924 2021
39
The complex interplay of climate, TBEV vector dynamics and TBEV infection rates in ticks-Monitoring a natural TBEV focus in Germany, 2009-2018. 61
33411799 2021
40
The Prevalence of Different Human Pathogenic Microorganisms Transmitted by Ixodes Tick Vectors in Belarus. 61
33107810 2021
41
Iripin-3, a New Salivary Protein Isolated From Ixodes ricinus Ticks, Displays Immunomodulatory and Anti-Hemostatic Properties In Vitro. 61
33732248 2021
42
Are host control strategies effective to eradicate tick-borne diseases (TBD)? 61
32918921 2021
43
Ticks (Acari: Ixodidae) on birds migrating to the island of Ponza, Italy, and the tick-borne pathogens they carry. 61
33113477 2021
44
Operational TBE incidence forecasts for Austria, Germany, and Switzerland 2019-2021. 61
33080518 2021
45
Identification and biochemical characterisation of a novel methionine aminopeptidase from the taiga tick Ixodes persulcatus. 61
33002807 2021
46
Sleep architecture, obstructive sleep apnea and functional outcomes in adults with a history of Tick-borne encephalitis. 61
33556106 2021
47
Immunogenicity and safety of rapid scheme vaccination against tick-borne encephalitis in HIV-1 infected persons. 61
33504405 2021
48
Contact-dependent transmission of Langat and tick-borne encephalitis virus in type I interferon receptor-1 deficient mice. 61
33504602 2021
49
ADAM15 Participates in Tick-Borne Encephalitis Virus Replication. 61
33208450 2021
50
Vaccination rate and adherence of tick-borne encephalitis vaccination in Germany. 61
33414049 2021

Variations for Tick-Borne Encephalitis

Expression for Tick-Borne Encephalitis

Search GEO for disease gene expression data for Tick-Borne Encephalitis.

Pathways for Tick-Borne Encephalitis

Pathways related to Tick-Borne Encephalitis according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.79 TLR3 RSAD2 OAS3 OAS2 OAS1 IL10
2
Show member pathways
13.57 IL10 IFNL3 IFNB1 IFNA1 CXCL13 CXCL11
3
Show member pathways
13.3 TLR3 IL10 CXCL13 CXCL11 CXCL10 CCR5
4
Show member pathways
13.04 RSAD2 OAS3 OAS2 OAS1 IL10 IFNL3
5
Show member pathways
12.77 CXCL13 CXCL11 CXCL10 CCR5 CCL3
6 12.7 TLR3 OAS3 OAS2 OAS1 IFNB1 IFNA1
7
Show member pathways
12.45 TLR3 IFNB1 IFNA1 DDX58 CXCL10
8 12.43 TLR3 RSAD2 OAS1 IL10 IFNA1 DDX58
9
Show member pathways
12.4 TLR3 RSAD2 OAS3 OAS2 OAS1 IL10
10
Show member pathways
12.36 TLR3 RSAD2 OAS3 OAS2 OAS1 IFNB1
11
Show member pathways
12.31 TLR3 IFNL3 IFNB1 IFNA1
12
Show member pathways
12.29 IL10 IFNL3 IFNB1 IFNA1
13
Show member pathways
12.29 RSAD2 OAS3 OAS2 OAS1 IFNB1 IFNA1
14
Show member pathways
12.24 IL10 CXCL13 CXCL11 CXCL10 CCR5 CCL3
15
Show member pathways
12.16 RSAD2 OAS3 OAS2 OAS1 IL10 IFNB1
16 12.15 OAS3 OAS2 OAS1 IFNB1 IFNA1
17 12.12 IL10 IFNB1 IFNA1 CD209
18 11.82 IFNB1 GSN CCL3
19 11.63 IL10 IFNB1 CD209
20 11.47 IL10 CXCL10 CCR5 CCL3
21 11.41 IFNL3 IFNB1 IFNA1
22 11.28 OAS1 IFNB1 CXCL10
23 11.23 CXCL13 CXCL11 CXCL10
24
Show member pathways
11.05 OAS1 IFNL3 DDX58
25 10.91 IL10 CXCL13 CXCL11 CXCL10 CCL3

GO Terms for Tick-Borne Encephalitis

Cellular components related to Tick-Borne Encephalitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 OAS1 IL10 IFNL3 IFNB1 IFNA1 GSN
2 extracellular space GO:0005615 9.4 TLR3 OAS3 IL10 IFNL3 IFNB1 IFNA1

Biological processes related to Tick-Borne Encephalitis according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.13 TLR3 RSAD2 OAS3 OAS2 OAS1 DDX58
2 viral process GO:0016032 10.08 SCRIB RSAD2 IVNS1ABP DDX58 CD209 CCR5
3 innate immune response GO:0045087 10.06 TLR3 RSAD2 OAS3 OAS2 OAS1 IFNL3
4 immune response GO:0006955 10.04 TLR3 IL10 CXCL13 CXCL11 CXCL10 CCR5
5 inflammatory response GO:0006954 10.03 TLR3 CXCL13 CXCL11 CXCL10 CCR5 CCL3
6 cell-cell signaling GO:0007267 9.97 CXCL13 CXCL11 CXCL10 CCR5 CCL3
7 cellular response to lipopolysaccharide GO:0071222 9.93 IL10 CXCL13 CXCL11 CXCL10 CCR5
8 chemotaxis GO:0006935 9.92 CXCL13 CXCL11 CXCL10 CCR5 CCL3
9 cytokine-mediated signaling pathway GO:0019221 9.91 IL10 IFNL3 IFNB1 IFNA1 CXCL10 CCR5
10 neutrophil chemotaxis GO:0030593 9.85 CXCL13 CXCL11 CXCL10 CCL3
11 cellular response to interferon-gamma GO:0071346 9.84 TLR3 GSN CCL3
12 positive regulation of tumor necrosis factor production GO:0032760 9.83 TLR3 DDX58 CCL3
13 cell chemotaxis GO:0060326 9.83 CXCL13 CCR5 CCL3
14 B cell differentiation GO:0030183 9.82 IL10 IFNB1 IFNA1
15 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.81 CXCL13 CXCL11 CXCL10
16 interferon-gamma-mediated signaling pathway GO:0060333 9.81 OAS3 OAS2 OAS1
17 chemokine-mediated signaling pathway GO:0070098 9.8 CXCL13 CXCL11 CXCL10 CCR5 CCL3
18 defense response GO:0006952 9.8 TLR3 IFNB1 IFNA1 CXCL13 CXCL11 CXCL10
19 positive chemotaxis GO:0050918 9.78 SCRIB CXCL10 CCL3
20 response to exogenous dsRNA GO:0043330 9.78 TLR3 IFNB1 IFNA1 DDX58
21 B cell proliferation GO:0042100 9.77 IL10 IFNB1 IFNA1
22 cellular response to exogenous dsRNA GO:0071360 9.74 TLR3 IFNB1 DDX58
23 type I interferon signaling pathway GO:0060337 9.73 RSAD2 OAS3 OAS2 OAS1 IFNB1 IFNA1
24 T cell chemotaxis GO:0010818 9.69 CXCL11 CXCL10 CCL3
25 response to cholesterol GO:0070723 9.65 CCR5 CCL3
26 positive regulation of immune response GO:0050778 9.65 RSAD2 IFNL3
27 signaling GO:0023052 9.63 CCR5 CCL3
28 negative regulation of viral genome replication GO:0045071 9.63 RSAD2 OAS3 OAS2 OAS1 IFNL3 IFNB1
29 release of sequestered calcium ion into cytosol by sarcoplasmic reticulum GO:0014808 9.62 CCR5 CCL3
30 detection of virus GO:0009597 9.62 TLR3 DDX58
31 astrocyte cell migration GO:0043615 9.61 SCRIB CCL3
32 regulation of ribonuclease activity GO:0060700 9.61 OAS3 OAS2 OAS1
33 response to virus GO:0009615 9.61 TLR3 RSAD2 OAS3 OAS2 OAS1 IVNS1ABP
34 defense response to virus GO:0051607 9.32 TLR3 RSAD2 OAS3 OAS2 OAS1 IFNL3

Molecular functions related to Tick-Borne Encephalitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.62 CXCL13 CXCL11 CXCL10 CCL3
2 nucleotidyltransferase activity GO:0016779 9.58 OAS3 OAS2 OAS1
3 CXCR chemokine receptor binding GO:0045236 9.54 CXCL13 CXCL11 CXCL10
4 CXCR3 chemokine receptor binding GO:0048248 9.43 CXCL13 CXCL11 CXCL10
5 double-stranded RNA binding GO:0003725 9.35 TLR3 OAS3 OAS2 OAS1 DDX58
6 2'-5'-oligoadenylate synthetase activity GO:0001730 9.33 OAS3 OAS2 OAS1
7 cytokine activity GO:0005125 9.23 IL10 IFNL3 IFNB1 IFNA1 CXCL13 CXCL11

Sources for Tick-Borne Encephalitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....